Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …
Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology
RR Shah, DR Shah - Drug safety, 2019 - Springer
Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …
Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
The role of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC)
has been vastly studied over the last decade. This has led to the rapid development of many …
has been vastly studied over the last decade. This has led to the rapid development of many …
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a …
J Liu, B Jin, H Su, X Qu, Y Liu - BMC cancer, 2019 - Springer
Background The epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell
lung cancer has been successfully treated with tyrosine kinase inhibitors (TKIs). Acquired …
lung cancer has been successfully treated with tyrosine kinase inhibitors (TKIs). Acquired …
Comparison of resistance spectra after first and second line osimertinib treatment detected by liquid biopsy
B Jóri, S Schatz, L Kaller, B Kah, J Roeper… - Cancers, 2021 - mdpi.com
Simple Summary Since the recent approval of osimertinib, a third generation tyrosine kinase
inhibitor (TKI) targeting EGFR in non-small cell lung cancer (NSCLC), tracing the resistance …
inhibitor (TKI) targeting EGFR in non-small cell lung cancer (NSCLC), tracing the resistance …
Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations
This study investigated the associations between image features extracted from tumor 18F-
fluorodeoxyglucose (FDG) uptake and genetic alterations in patients with lung cancer. A …
fluorodeoxyglucose (FDG) uptake and genetic alterations in patients with lung cancer. A …
Case report: dacomitinib may not benefit patients who develop rare compound mutations after later-line osimertinib treatment
HS Li, GJ Yang, Y Wang - Frontiers in oncology, 2021 - frontiersin.org
The acquired EGFR C797X mutation has been identified as the most notable resistance to
osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also …
osimertinib, and novel secondary mutations of EGFR L718 and L792 residues have also …
CRISPER/CAS system, a novel tool of targeted therapy of drug-resistant lung cancer
VA Kordkheyli, M Rashidi, Y Shokri… - Advanced …, 2021 - pmc.ncbi.nlm.nih.gov
Lung cancer (LC) is the most common cause of cancer-related death worldwide. Patients
with LC are usually diagnosed at advanced phases. Five-year survival rate in LC patients is …
with LC are usually diagnosed at advanced phases. Five-year survival rate in LC patients is …
Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients
In radiomics research, the issue of different instruments being used is significant. In this
study, we compared three correction methods to reduce the batch effects in radiogenomic …
study, we compared three correction methods to reduce the batch effects in radiogenomic …
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases: Miniperspective
J Niggenaber, J Hardick, J Lategahn… - Journal of Medicinal …, 2019 - ACS Publications
The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor)
and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer …
and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer …